LLYD Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.90 |
| 52 Week High | US$18.50 |
| 52 Week Low | US$9.40 |
| Beta | 0.42 |
| 11 Month Change | -0.88% |
| 3 Month Change | 2.42% |
| 1 Year Change | 63.40% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 200.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLYD | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | 2.4% | -5.5% | -2.4% |
| 1Y | 63.4% | -14.2% | 195.1% |
Return vs Industry: LLYD exceeded the AR Pharmaceuticals industry which returned -14.2% over the past year.
Return vs Market: LLYD underperformed the AR Market which returned 198.8% over the past year.
Price Volatility
| LLYD volatility | |
|---|---|
| LLYD Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in AR Market | 8.7% |
| 10% least volatile stocks in AR Market | 5.0% |
Stable Share Price: LLYD has not had significant price volatility in the past 3 months.
Volatility Over Time: LLYD's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLYD fundamental statistics | |
|---|---|
| Market cap | US$827.06b |
| Earnings (TTM) | US$7.34b |
| Revenue (TTM) | US$38.92b |
113.4x
P/E Ratio21.4x
P/S RatioIs LLYD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLYD income statement (TTM) | |
|---|---|
| Revenue | US$38.92b |
| Cost of Revenue | US$7.49b |
| Gross Profit | US$31.43b |
| Other Expenses | US$24.09b |
| Earnings | US$7.34b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | 8.15 |
| Gross Margin | 80.75% |
| Net Profit Margin | 18.86% |
| Debt/Equity Ratio | 212.9% |
How did LLYD perform over the long term?
See historical performance and comparison